[PDF][PDF] S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3

HB Schonthaler, J Guinea-Viniegra, SK Wculek… - Immunity, 2013 - cell.com
HB Schonthaler, J Guinea-Viniegra, SK Wculek, I Ruppen, P Ximénez-Embún…
Immunity, 2013cell.com
Psoriasis is a common heterogeneous inflammatory skin disease with a complex
pathophysiology and limited treatment options. Here we performed proteomic analyses of
human psoriatic epidermis and found S100A8-S100A9, also called calprotectin, as the most
upregulated proteins, followed by the complement component C3. Both S100A8-S100A9
and C3 are specifically expressed in lesional psoriatic skin. S100A9 is shown here to
function as a chromatin component modulating C3 expression in mouse and human cells by …
Summary
Psoriasis is a common heterogeneous inflammatory skin disease with a complex pathophysiology and limited treatment options. Here we performed proteomic analyses of human psoriatic epidermis and found S100A8-S100A9, also called calprotectin, as the most upregulated proteins, followed by the complement component C3. Both S100A8-S100A9 and C3 are specifically expressed in lesional psoriatic skin. S100A9 is shown here to function as a chromatin component modulating C3 expression in mouse and human cells by binding to a region upstream of the C3 start site. When S100A9 was genetically deleted in mouse models of skin inflammation, the psoriasis-like skin disease and inflammation were strongly attenuated, with a mild immune infiltrate and decreased amounts of C3. In addition, inhibition of C3 in the mouse model strongly reduced the inflammatory skin disease. Thus, S100A8-S100A9 can regulate C3 at the nuclear level and present potential new therapeutic targets for psoriasis.
cell.com